The PE Ratio as of December 2024 (TTM) for GH Research PLC (GHRS) is -8.97

According to GH Research PLC’s latest financial reports and current stock price. The company's current PE Ratio is -8.97. This represents a change of -24.30% compared to the average of -11.85 of the last 4 quarters.

GH Research PLC (GHRS) Historical PE Ratio (quarterly & annually)

How has GHRS PE Ratio performed in the past?

The mean historical PE Ratio of GH Research PLC over the last ten years is -1515.84. The current -8.97 PE Ratio has changed -40.82% with respect to the historical average. Over the past ten years (40 quarters), GHRS's PE Ratio was at its highest in in the September 2022 quarter at 26.31. The PE Ratio was at its lowest in in the March 2020 quarter at -7092.11.

GH Research PLC (GHRS) PE Ratio by Quarter and Year

Discovering the peaks and valleys of GH Research PLC PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

GH Research PLC (GHRS) Average PE Ratio

How has GHRS PE Ratio performed in the past?

The current PE Ratio of GH Research PLC (GHRS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

GH Research PLC (GHRS) PE Ratio vs. Peers

How is GHRS’s PE Ratio compared to its peers?

GH Research PLC’s PE Ratio is less than Molecular Partners AG (-2.46), less than MediciNova, Inc. (-0.04), less than Anebulo Pharmaceuticals, Inc. (-5.30), greater than Champions Oncology, Inc. (-178.90), greater than Cyteir Therapeutics, Inc. (-9.12), less than Mineralys Therapeutics, Inc. (-4.16), less than Eliem Therapeutics, Inc. (0), greater than Janux Therapeutics, Inc. (-50.66), less than Rezolute, Inc. (-4.44), less than PMV Pharmaceuticals, Inc. (-1.47), less than Pharvaris N.V. (-7.35), less than PepGen Inc. (-1.51), less than Monte Rosa Therapeutics, Inc. (-4.84), less than Design Therapeutics, Inc. (-7.53), less than Werewolf Therapeutics, Inc. (-1.08), less than Ikena Oncology, Inc. (-1.24), less than Stoke Therapeutics, Inc. (-6.05), less than Arcus Biosciences, Inc. (-5.39), less than Cullinan Oncology, Inc. (-4.99), less than Annexon, Inc. (-6.23), greater than Structure Therapeutics Inc. (-12.61), less than Relay Therapeutics, Inc. (-1.72),

Build a custom stock screener for GH Research PLC (GHRS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like GH Research PLC using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

GH Research PLC (GHRS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like GH Research PLC or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.